Axillary lymph node dissection (ALND) is a procedure to remove lymph nodes in the underarm area when breast cancer has spread, aiming to prevent further spread and recurrence. The procedure involves ...

Omitting axillary lymph node dissection does not increase the risk for recurrence or compromise 5-year overall survival outcomes in patients with early-stage, node-negative breast cancer with sentinel ...

The word “dissection” may conjure images of a high school biology lab full of frogs or sheep’s eyeballs in various stages of deconstruction. But an axillary node dissection is a decidedly different ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Dye is injected into the breast, one to four of the nodes is identified with a probe and removed to see if cancer cells are present. Lymph nodes are small organs, typically ranging from the size of a ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

More women could potentially be spared an axillary lymph node dissection -- the surgical removal of 10-20 lymph nodes -- a procedure that causes disabling arm swelling in up to 25% of women, according ...

A total of 333 patients were included in the study. The SLN could be identified in 328 out of 333 patients, calculating an identification rate of 98.5%. SLNs were positive for metastases in 128 out of ...